Cerebrospinal fluid

Handbook of Multiple Sclerosis, Third Edition

Volumn , Issue , 2001, Pages 347-375

  Whitaker, John N ^a,b   Bashir, Khurram ^a   Benveniste, Etty N ^c  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 59349118265     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (245)

1. Merritt HH, Fremont-Smith F. The Cerebrospinal Fluid. Philadelphia, Saunders, 1937, pp 63-67, 270-272.
2. Fishman RA. Cerebrospinal Fluid in Diseases of the Nervous System. Philadelphia, Saunders, 1992, pp 213-214.
3. Walsh MJ, Tourtellotte WW. The cerebrospinal fluid in multiple sclerosis. In: Hallpike JF, Adams CMW, Tourtellotte WW, eds. Multiple Sclerosis. Baltimore, Williams & Wilkins, 1983, pp 275-358.
4. Whitaker JN, Snyder DS. Myelin components in the cerebrospinal fluid in diseases affecting central nervous system myelin. Clin Immunol Allergy 2:469-482, 1982.
5. Hauser SL, Reinherz EL, Hoban CJ, Schlossman SF, Weiner HL. CSF cells in multiple sclerosis: Monoclonal antibody analysis and relationship to peripheral blood T-cell subsets. Neurology 33:575-579, 1983.
6. Tourtellotte WW. The cerebrospinal fluid in multiple sclerosis. In: Vinken PJ, Bruyn GW, Klawans HL, Koetsier JC, eds. Handbook of Clinical Neurology, vol 47. Amsterdam: Elsevier, 1985, pp 79-130.
7. Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, OReilly K, Priore RL, Pullicino PM, Scherokman BJ, Wende K, Weinstock-Guttman B, Whitham RH. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFN beta-1a) for relapsing multiple sclerosis. J Neuroimmunol 93(1-2):8-14, 1999.
8. Prineas JW. The Neuropathology of Multiple Sclerosis. In: Vinken PJ, Bruyn GW, Klawans HL, Koetsier JC, eds. Handbook of Clinical Neurology, vol 47. Amsterdam: Elsevier, 1985, pp 213-257.
9. Cohen S, Bannister R. Immunoglobulin synthesis within the central nervous system in disseminated sclerosis. Lancet 1:366-367, 1967.
10. Sandberg-Wollheim M, Zetterwall L, Muller R. In vitro synthesis of IgG by cells from the cerebrospinal fluid in a patient with multiple sclerosis. Clin Exp Immunol 4:401-405, 1969.
11. Henriksson A, Kam-Hansen S, Link H. IgM, IgA and IgG producing cells in cerebrospinal fluid in a patient with multiple sclerosis. Clin Exp Immunol 62:176-184, 1985.
12. Weber T, Rieckmann P, Jurgens S, Prange HW, Felgenhauer K. Immunocytochemical analysis of immunoglobulin-containing cells in CSF and blood in inflammatory disorders of the central nervous system. J Neurol Sci 86:61-72, 1988.
13. Hickey WF, Cohen JA, Burns JB. A quantitative immunohistochemical comparison of actively versus adoptively induced experimental allergic encephalomyelitis in the Lewis rat. Cell Immunol 109:272-281, 1987.
14. Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol 25:1-6, 1977.
15. Cruzner ML, Hayes GM, Newcombe J, Woodroofe MN. The nature of inflammatory components during demyelination in multiple sclerosis. J Neuroimmunol 20:203-209, 1988.
16. Hauser SL, Bhan AK, Gilles FH, Hoban CJ, Reinherz EL, Weiner HL. Immunohistochemical staining of human brain with monoclonal antibodies that identify lymphocytes, nomocytes and the Ia antigen. J Neuroimmunol 5:197-205, 1983.
17. Paterson PY, Day ED, Whitacre CC. Neuroimmunologic diseases: Effector cell responses and immunoregulatory mechanisms. Immunol Rev 55:89-120, 1981.
18. Paterson PY, Day ED. Current perspectives of neuroimmunologic disease: Multiple sclerosis and experimental allergic encephalomyelitis (1, 2). Clin Immunol Rev 1:581-697, 1982.
19. Traugott U, Scheinberg LC, Raine CS. On the presence of Ia positive endothelial cells and astrocytes in multiple sclerosis and its relevance to antigen presentation. J Neuroimmunol 8:1-9, 1985.
20. Wood JH. Neurobiology of cerebrospinal fluid. In: Wood JH, ed. Physiology, Pharmacology, and Dynamics of Cerebrospinal fluid, vol 1. New York: Plenum Press, 1980, pp 1-16.
21. Betz LA, Goldstein GM, Katzman R. Basic neurochemistry: molecular, cellular, and medical aspects. In: Siegal GJ, ed. Blood-Brain-Cerebrospinal Fluid Barriers. New York: Raven Press, 1989, pp 591-606.
22. Hafler DA, Weiner HL. In vivo labeling of blood T cells: Rapid traffic into cerebrospinal fluid in multiple sclerosis. Ann Neurol 22:89-93, 1987.
23. Burns J, Zweiman B, Lisak R. Tetanus toxoid reactive T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. Immunol Commun 13:361-369, 1984.
24. Svenningsson A, Andersen O, Edsbagge M, Stemme S. Lymphocyte phenotype and subset distribution in normal cerebrospinal fluid. J Neuroimmunol 63:39-46, 1995.
25. Brinkman CJJ, Nillesen WM, Hommes OR. T-cell subpopulations in blood and cerebrospinal fluid of multiple sclerosis patients: Effect of cyclophosphamide. Clin Immunol Immunopathol 29:341-348, 1983.
26. Bamborschke S, Heiss WD. Cerebrospinal fluid and peripheral blood leukocyte subsets in acute inflammation of the CNS. J Neurol Sci 79:1-2, 1987.
27. Kleine TO, Albrecht J, Zofel P. Flow cytometry of cerebrospinal fluid (CSF) lymphocytes: Alterations of blood CSF ratios of lymphocyte subsets in inflammation disorders of human central nervous system (CNS). Clin Chem Lab Med 37(3):231-241, 1999.
28. Elfont RM, Griffin DE, Goldstein GW. Enhanced endothelial cell adhesion of human cerebrospinal fluid lymphocytes. Ann Neurol 38(3):405-413, 1995.
29. DeFreitas EC, Sandberg-Wollheim M, Schonely K, et al. Regulation of interleukin-2 receptors on T cells from multiple sclerosis patients. Proc Natl Acad Sci USA 83:2637-2641, 1986.
30. Tournier-Lasserve E, Lyon-Caen O, Roullet E, et al. IL-2 receptor and HLA class II antigens on cerebrospinal fluid cells of patients with multiple sclerosis and other neurological diseases. Clin Exp Immunol 67:581-586, 1987.
31. Noronha A, Richman D, Arnason B. Multiple sclerosis: Activated cells in cerebrospinal fluid in acute exacerbations. Ann Neurol 18:722-725, 1985.
32. Reder AT, Arnason BGW. Immunology of multiple sclerosis. In: Vinken PJ, Bruyn GW, Klawans HC, eds. Handbook of Clinical Neurology, vol 47. Amsterdam: Elsevier, 1985, pp 337-395.
33. Polman CH, deGroot CJA, Koetsier JC, Sminia T, Veerman AJP. Cerebrospinal fluid cells in multiple sclerosis and other neurological disease: An immunocytochemical study. J Neurol 234:19-22, 1987.
34. Cher DJ, Mosmann TR. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol 138(11):3688-3694, 1987.
35. Seder RA, Paul EW. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 12:635-673, 1994.
36. Powrie F, Coffman RL. Cytokine regulation of T-cell function: Potential for therapeutic intervention. Immunol Today 14(6):270-274, 1993.
37. Mosmann TR, Coffman RL. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-173, 1989.
38. Kuchroo VK, Martin CA, Greer JM, Shyre-Te J, Sobel RA, Dorf ME. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J Immunol 151:4371-4382, 1993.
39. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA. Surface expression of a4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177(1):57-68, 1993.
40. Rotteveel FTM, Lucan CJ. T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis. Immunol Res 9:287-297, 1990.
41. Antonen J, Syrjala P, Oikarinen R, Frey H, Krohn K. Acute multiple sclerosis exacerbations are characterized by low cerebrospinal fluid suppressor/cytotoxic T-cells. Acta Neurol Scand 75:156-160, 1987.
42. Martino G, Olsson T, Fredrikson S, Hojeberg B, Kostulas V, Grimaldi LME, Link H. Cells producing antibodies specific for myelin basic protein region 70-89 are predominant in cerebrospinal fluid from patients with multiple sclerosis. Eur J Immunol 21:2971-2976, 1991.
43. Baig S, Olsson T, Yu-Ping J, B Höjeberg, Cruz M, Link H. Multiple sclerosis: Cells secreting antibodies against myelin-associated glycoprotein are present in cerebrospinal fluid. Scand J Immunol 33:73-79, 1991.
44. Soderstrom M, Link H, Xu Z, Fredriksson S. Optic neuritis and multiple sclerosis: Anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF. Neurology 43: 1215-1222, 1993.
45. Sellebjerg FT, Frederiksen JL, Olsson T. Anti-myelin basic protein and anti-proteolipid protein antibody-secreting cells in the cerebrospinal fluid of patients with acute optic neuritis. Arch Neurol 51:1032-1036, 1994.
46. Levinson AI, Lisak RP, Zweiman B. A microtechnique for PHA transformation of 5000 separated lymphocytes. Cell Immunol 14:321-326, 1974.
47. Lisak RP, Zweiman B. In vitro cell-mediated immunity of cerebrospinal-fluid lymphocytes to myelin basic protein in primary demyelinating disease. N Engl J Med 297:850-853, 1977.
48. Levinson AI, Sandberg-Wollheim M, Lisak RP. Analysis of B-cell activation of cerebrospinal fluid lymphocytes in multiple sclerosis. Neurology 33:1305-1310, 1983.
49. Lisak RP, Zweiman B, Whitaker JN. Spinal fluid basic protein immunoreactive material and spinal fluid lymphocyte reactivity to basic protein. Neurology 31:180-182, 1981.
50. Noronha ABC, Richman DP, Arnason BGW. Detection of in vivo stimulated cerebrospinalfluid lymphocytes by flow cytometry in patients with multiple sclerosis. N Engl J Med 303: 713-717, 1980.
51. Birnbaum G, Kotilinek L, Schwartz M, Sternad M. Spinal fluid lymphocytes responsive to autologous and allogeneic cells in multiple sclerosis and control individuals. J Clin Invest 74:1307-1317, 1984.
52. Birnbaum G, Aubitz S, Kotilinek L. Search for autonomously proliferating spinal fluid lymphocytes in patients with multiple sclerosis. Neurology 38:28-30, 1988.
53. Maier CC, Blalock JE. Cloning and sequencing immunoglobulin and T-cell receptor variable regions involved in neuroimmune disorders. Methods Neurosci 24:321-334, 1995.
54. Frei K, Leist TP, Meager A. Production of B-cell stimulatory factor-2 and interferon-γ in the central nervous system during viral meningitis and encephalitis: Evaluation in a murine model infection and in patients. J Exp Med 168:449-453, 1988.
55. Harlow E, Lane D. Antibodies: A Laboratory Manual. NY, Cold Spring Harbor Laboratory, 1988, pp 7-22.
56. Mendell JR, Kolkin S, Kissel JT, Weiss KL, Chakeres DW, Rammohan KW. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 37:1291-1294, 1987.
57. Thomas PK, Walker RWH, Rudge P, et al. Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination. Brain 110:53-76, 1987.
58. Kabat EA, Moore DH, Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to serum proteins. J Clin Invest 21:571-577, 1942.
59. Tiselius A, Kabat EA. An electrophoretic study of immune sera and purified antibody preparations. J Exp Med 69:119-131, 1939.
60. Kabat EA. Getting started 50 years ago-experiences, perspective, and problems of the first 21 years. Annu Rev Immunol 1:1-32, 1983.
61. Bibel DJ. Milestones in immunology. Berlin, Springer-Verlag, 1988, pp 94-98.
62. Kabat EA, Landow H, Moore DH. Electrophoretic patterns of concentrated cerebrospinal fluid. Proc Soc Exp Biol Med 49:260-263, 1942.
63. Kabat EA, Freedman DA, Murray JP, Knaub V. A study of the crystalline albumin, gamma globulin and total protein in the cerebrospinal fluid of one hundred cases of multiple sclerosis and in other diseases. Am J Med Sci 219:55-64, 1950.
64. Grossman RI, Gonzalez-Scarano F, Atlas SW, Galetta S, Silberberg DH. Multiple sclerosis: Gadolinium enhancement in MR imaging. Radiology 161:721-725, 1986.
65. Mingioli ES, Strober W, Tourtellotte WW, Whitaker JN, McFarlin DE. Quantitation of IgG, IgA and IgM in the CSF by radioimmunoassay. Neurology 28:991-995, 1978.
66. Tourtellotte WW, Parker PA. Multiple sclerosis: Correlation between immunoglobulin-G in cerebrospinal fluid and brain. Science 154:1044-1046, 1966.
67. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders: III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 37:397-401, 1977.
68. Lefvert AK, Link H. IgG production within the central nervous system: A critical review of proposed formulae. Ann Neurol 17:13-20, 1985.
69. Tourtellotte W. On cerebrospinal fluid immunoglobulin G (IgG) quotients in multiple sclerosis and other diseases: A review and a new formula to estimate the amount of IgG synthesized per day by the central nervous system. J Neurol Sci 10:279-304, 1970.
70. Tourtellotte WW, Potvin AR, Fleming JO, et al. Multiple sclerosis: Measurement and validation of central nervous system IgG synthesis rate. Neurology 30:240-244, 1980.
71. Tourtellotte WW, Staugaitis SM, Walsh MJ, et al. The basis of intra-blood-brain-barrier IgG synthesis. Ann Neurol 17:21-27, 1985.
72. Whitaker JN. Quantitation of the synthesis of immunoglobulin G within the central nervous system. Ann Neurol 17:11-12, 1985.
73. Rudick RA, Whitaker JN. Cerebrospinal fluid tests for multiple sclerosis. In: Scheinberg P, ed. Neurology/Neurosurgery Update Series, vol. 7 (lesson 21). Princeton, NJ, CPEC, 1987, pp 1-8.
74. Lowenthal A, van Sande M, Karcher D. The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins. J Neurochem 6:51-56, 1960.
75. Farrell MA, Kaufmann JCE, Gilbert JJ, Noseworthy JH, Armstrong HA, Ebers GC. Oligoclonal bands in multiple sclerosis: clinical-pathological correlation. Neurology 35:212-218, 1985.
76. Mattson DH, Roos RP, Arnason BGW. Isoelectric focusing of IgG eluted from multiple sclerosis and subacute sclerosing panencephalitis brains. Nature 287:335-337, 1980.
77. Walsh MJ, Tourtellotte WW. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med 163:41-53, 1986.
78. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 6(3):259-274, 1996.
79. Raine CS, Cannella B, Hauser SL, Genain CP. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen-specific antibody mediation. Ann Neurol 46(2):144-160, 1999.
80. Zeman AZJ, Keir G, Luxton R, Thompson EJ. Serum oligoclonal IgG is a common and persistent finding in multiple sclerosis, and has a systemic source. QJM 89(3):187-193, 1996.
81. Nagelkerken LM, Out TA. In vitro stimulated peripheral blood lymphocytes from multiple sclerosis patients produce idiotypes of oligoclonal CSF IgG. J Immunol 131:2328-2331, 1983.
82. Laurenzi MA, Mavra M, Kam-Hansen S, Link H. Oligoclonal IgG and free light chains in multiple sclerosis demonstrated by thin-layer polyacrylamide gel isoelectric focusing and immunofixation. Ann Neurol 8:241-247, 1980.
83. Keir G, Walker RWH, Thompson EJ. Oligoclonal immunoglobulin M in cerebrospinal fluid from multiple sclerosis patients. J Neurol Sci 57:281-285, 1982.
84. Grimaldi LME, Roos RP, Nalefski EA, Arnason BGW. Oligoclonal IgA bands in multiple sclerosis and subacute sclerosing panencephalitis. Neurology 35:813-817, 1985.
85. Bass BH, Armstrong H, Weinshenker B, Ebers GC, Noseworthy JH, Rice GPA. Interpretation of single band patterns in CSF protein electrophoresis. Can J Neurol Sci 15:20-22, 1988.
86. Kostulas VK, Link H, Lefvert AK. Oligoclonal IgG bands in cerebrospinal fluid: Principles for demonstration and interpretation based on findings in 1114 neurological patients. Arch Neurol 44:1041-1044, 1987.
87. Miller JR, Burke A, Bever CT. Occurrence of oligoclonal bands in multiple sclerosis and other CNS diseases. Ann Neurol 13:53-58, 1983.
88. Moulin D, Paty DW, Ebers GC. The predictive value of cerebrospinal fluid electrophoresis in '‘possible’’ multiple sclerosis. Brain 106:809-816, 1983.
89. Stendahl-Brodin L, Link H. Optic neuritis: Oligoclonal bands increase the risk of multiple sclerosis. Acta Neurol Scand 67:301-304, 1983.
90. Mattson DH, Roos RP, Arnason BW. Comparison of agar gel electrophoresis and isoelectric focusing in multiple sclerosis and subacute sclerosing panencephalitis. Ann Neurol 9:34-41, 1981.
91. Thompson EJ, Kaufmann P, Rudge P. Sequential changes in oligoclonal patterns during the course of multiple sclerosis. J Neurol Neurosurg Psychiatry 46:115-118, 1983.
92. Thompson AJ, Hutchinson M, Martin EA, Mansfield M, Whelan A, Feighery C. Suspected and clinically definite multiple sclerosis: The relationship between CSF immunoglobulins and clinical course. J Neurol Neurosurg Psychiatry 48:989-994, 1985.
93. Bulman DE, Pandey JP, Ebers GC. Gm allotypes in multiple sclerosis. In: Lowenthal A, Raus J, eds. Cellular and Humoral Immunological Components of Cerebrospinal Fluid in Multiple Sclerosis. New York: Plenum, 1987, pp 81-86.
94. Salier JP, Goust JM, Pandey JP, Fudenberg HH. Preferential synthesis of the G1m(1) allotype of IgG in the central nervous system of multiple sclerosis patients. Science 213:1400-1402, 1981.
95. Ebers GC. A study of CSF idiotypes in multiple sclerosis. Scand J Immunol 16:151-161, 1982.
96. Gerhard W, Taylor A, Sandberg-Wollheim M, Koprowski H. Longitudinal analysis of three intrathecally produced immunoglobulin subpopulations in MS patients. J Immunol 134: 1555-1560, 1985.
97. Tachovsky TG, Sandberg-Wollheim M, Baird LG. Rabbit antihuman CSF IgG: I. Characterization of anti-idiotype antibodies produced against MS CSF and detection of cross-reactive idiotypes in several MS CSF. J Immunol 129:764-770, 1982.
98. Zhou SR, Maier CC, Mitchell GW, LaGanke CC, Blalock JE, Whitaker JN. A cross-reactive anti-myelin basic protein idiotope in cerebrospinal fluid cells in multiple sclerosis. Neurology 50(2):411-417, 1998.
99. LaGanke C, Freeman DW, Whitaker JN. Cross-reactive idiotypy in cerebrospinal fluid immunoglobulins in multiple sclerosis. Ann Neurol 47:87-92, 2000.
100. Link H, Muller H. Immunoglobulins in multiple sclerosis and infections of the nervous system. Arch Neurol 25:326-344, 1971.
101. Rudick RA, Pallant A, Bidlack JM, Herndon RM. Free kappa light chains in multiple sclerosis spinal fluid. Ann Neurol 20:63-69, 1986.
102. Rudick RA. Free light chain of immunoglobulins in multiple sclerosis: A Putative index of the intrathecal humoral immune response. In: Lowenthal A, Raus J, eds. Cellular and Humoral Immunological Components of Cerebrospinal Fluid in Multiple Sclerosis. New York: Plenum Press, 1987, pp 187-200.
103. Knopf PM, Harling-Berg CJ, Cserr HF, Basu D, Sirulnick EJ, Nolan SC, Park JT, Keir G, Thompson EJ, Hickey WF. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: Tissue entry and local retention of antigen-specific B cells. J Immunol 161:692-701, 1998.
104. Ivanainen MV. The significance of abnormal immune responses in patients with multiple sclerosis. J Neuroimmunol 1:141-172, 1981.
105. Vartdal F, Vandvik B, Michaelsen TE, Loe K, Norrby E. Neurosyphilis: Intrathecal synthesis of oligoclonal antibodies to Treponema pallidum. Ann Neurol 11:35-40, 1982.
106. Vandvik B, Norrby E, Steen-Johnson J, Stensvold K. Mumps meningitis: Procerebrospinal fluid. Eur Neurol 17:13-22, 1978.
107. Vandvik B, Norrby E. Oligoclonal IgG antibody response in the central nervous system to different measles virus antigens in subacute sclerosing panencephalitis. Proc Natl Acad Sci USA 70:1060-1063, 1973.
108. Vartdal F, Norrby E. Viral and bacterial antibody responses in multiple sclerosis. Ann Neurol 8:248-255, 1980.
109. Whitaker JN, Chou CHJ, Chou FCH, Kibler RF. Molecular internalization of a region of myelin basic protein. J Exp Med 146:317-331, 1977.
110. Coyle PK, Brooks BR, Hirsh RL, et al. Cerebrospinal-fluid lymphocyte populations and immune complexes in active multiple sclerosis. Lancet 2:229-232, 1980.
111. Panitch HS, Hooper CJ, Johnson KP. CSF antibody to myelin basic proteins: Measurement in patients with multiple sclerosis and subacute sclerosing panencephalitis. Arch Neurol 37: 206-209, 1980.
112. Bashir RM, Whitaker JN. Molecular features of immunoreactive myelin basic protein in cerebrospinal fluid of persons with multiple sclerosis. Ann Neurol 7:50-57, 1980.
113. Warren KG, Catz I. Diagnostic value of cerebrospinal fluid anti-myelin basic protein in patients with multiple sclerosis. Ann Neurol 20:20-25, 1986.
114. Warren KG, Catz I, Steinman L. Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: The minimal B-cell epitope and a model of its features. Proc Natl Acad Sci USA 92(24):11061-11065, 1995.
115. Wucherpfennig KW, Catz I, Hausmann S, Strominger JL, Steinman L, Warren KG. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients-Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest 100(5):1114-1122, 1997.
116. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nature Med 5(2):170-175, 1999.
117. Warren KG, Catz I, Johnson E, Mielke B. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann Neurol 35:280-289, 1994.
118. Trotter JL, Wegerscheide CL, Garvey WF. Immunoreactive myelin proteolipid protein-like activity in cerebrospinal fluid and serum of neurologically impaired patients. Ann Neurol 14:464-469, 1983.
119. Yanagisawa K, Quarles RH, Johnson D, Brady RO, Whitaker JN. A derivative of myelinassociated glycoprotein (dMAG) in cerebrospinal fluid of normal subjects and patients with neurological disease. Ann Neurol 18:464-469, 1985.
120. Clapshaw PA, HW Müller, H Wiethölter, Seifert W. Simultaneous measurement of 2':3' cyclic-nucleotide 3' phosphodiesterase and RNase activities in sera and spinal fluids of multiple sclerosis patients. J Neurochem 42:12-15, 1984.
121. Neu IS. Essential fatty acids in the serum and cerebrospinal fluid of multiple sclerosis patients. Acta Neurol Scand 67:151-163, 1984.
122. Reiber H, Voss W. Cholesterol ester hydrolase activity in human cerebrospinal fluid. J Neurochem 34:1324-1326, 1980.
123. Ginns E, French J. A radioassay for GM1 ganglioside concentration in cerebrospinal fluid. J Neurochem 35:977-982, 1980.
124. Pitkänen ASL, Halonen TO, HO Kilpeläinen, Riekkinen PJ, et al. Cholesterol esterase activity in cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci 74:45-53, 1986.
125. Massaro AR, Michetti F, Laudisio A, Bergonzi P. Myelin basic protein and S-100 antigen in cerebrospinal fluid of patients with multiple sclerosis in the acute phase. Ital J Neurol Sci 6:53-56, 1985.
126. Massaro AR, Carbone G. Cerebrospinal fluid markers in multiple sclerosis. In: Crescenzi GS, ed. A Multidisciplinary Approach to Myelin Disease. New York: Plenum, 1988, pp 267-274.
127. Bever CT, Whitaker JN. Proteinases in inflammatory demyelinating disease. Springer Semin Immunopath 8:235-250, 1985.
128. Inuzuka T, Sato S, Baba H, Mujatake T. Neutral protease in cerebrospinal fluid from patients with multiple sclerosis and other neurological diseases. Acta Neurol Scand 76:18-23, 1987.
129. Fredrikson S, Link H, Eneroth P. CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurol Scand 75:352-355, 1987.
130. Frederickson S, Eneroth P, Link H. Intrathecal production of neopterin in aseptic meningoencephalitis and multiple sclerosis. Clin Exp Immunol 67:76-81, 1987.
131. Sorensen KV. Somatostatin in multiple sclerosis. Acta Neurol Scand 75:161-167, 1987.
132. Gallo P, Piccinno M, Pagni S, Tavolato B. Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 24:795-797, 1988.
133. Welgus HG, Campbell EJ, Cury JD, Eisen AZ, Senior RM, Wilhelm SM, Goldberg GI. Neutral metalloproteinases produced by human mononuclear phagocytes: Enzyme profile, regulation and expression during cellular development. J Clin Invest 86:1496-1502, 1990.
134. Conca W, Willmroth F. Human T lymphocytes express a member of the matrix metalloproteinase gene family. Arthritis Rheum 37:951-956, 1994.
135. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 154:4379-4389, 1995.
136. Uhm JH, Dooley NP, Oh LYS, Yong VW. Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia 22(1):53-63, 1998.
137. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. Metalloproteinases: A review. Crit Rev Oral Biol Med 4:197-250, 1993.
138. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, et al. Processing of tumour necrosis factoralpha precursor by metalloproteinases. Nature 370(6490):555-557, 1994.
139. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 181(3):1205-1210, 1995.
140. Arribas J, Coodly L, Vollmer P, Kishimoto TK, Rose-John S, Massague J. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 271(19):11376-11382, 1996.
141. Chandler S, Miller KM, Clements JM, Lury J, Corkill D, Anthony DCC, Adams SE, Gearing AJH. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: An overview. J Neuroimmunol 72:155-161, 1997.
142. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase-B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 192(3):1175-1181, 1993.
143. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 201(3):223-226, 1995.
144. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, Newcombe J. The expression of tissue-type plasminogen-activator, matrix metalloproteinases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution. J Neuropathol Exp Neurol 55:1194-1204, 1996.
145. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 41:29-34, 1992.
146. Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S, Miller KM, Hauser SL, Kappos L. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 121:2327-2334, 1998.
147. Trojano M, Avolio C, Liuzzi GM, Ruggeiri M, Defazio G, Liguori M, Santacroce MP, Paolicelli D, Giuliani F, Riccio P, Livrea P. Changes of serum sICAM-1 and MMP-9 induced by rIFNß-1b treatment in relapsing-remitting MS. Neurology 53:1402-1408, 1999.
148. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis-A longitudinal clinical and MRI study. Brain 122:191-197, 1999.
149. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson P-B, Stabler G, Miller K. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53:1397-1401, 1999.
150. Herndon RM, Johnson M. A method for the electron microscopic study of cerebrospinal fluid sediment. J Neuropathol Exp Neurol 29:320-330, 1970.
151. Cohen SR, Herndon RM, McKhann GM. Radioimmunoassay of myelin basic protein in spinal fluid: An index of active demyelination. N Engl J Med 295:1455-1457, 1976.
152. Whitaker JN. Myelin encephalitogenic protein fragments in cerebrospinal fluid of persons with multiple sclerosis. Neurology 27:911-920, 1977.
153. Gupta MK, Whitaker JN, Johnson C, Goren H. Measurement of immunoreactive myelin basic protein peptide (45-89) in cerebrospinal fluid. Ann Neurol 23:273-280, 1988.
154. Whitaker JN, Herman PK. Human myelin basic protein peptide 69-89: Immunochemical features and use in immunoassays of cerebrospinal fluid. J Neuroimmunol 19:47-57, 1988.
155. Whitaker JN. Indicators of disease activity in multiple sclerosis: Studies of myelin basic protein-like materials. Ann NY Acad Sci 436:140-150, 1984.
156. Morell P, Quarles RH, Norton WT. Formation, structure and biochemistry of myelin. In: Siegel G, Agranoff B, Albers RW, Molinoff P, eds. Basic Neurochemistry. New York: Raven Press, 1989, pp 109-136.
157. Kamholz J, deFerra F, Puckett C, Lazzarini RA. Identification of three forms of human myelin basic protein by cDNA cloning. Proc Natl Acad Sci USA 83:4962-4966, 1986.
158. Karlsson B, Alling C. Molecular size of myelin basic protein immunoactivity in spinal fluid. J Neuroimmunol 6:141-150, 1984.
159. Warren KG, Catz I. The relationship between levels of cerebrospinal fluid myelin basic protein and IgG measurements in patients with multiple sclerosis. Ann Neurol 17:475-480, 1985.
160. Thompson AJ, Hutchinson M, Brazil J, Feighery C, Martin EA. A clinical and laboratory study of benign multiple sclerosis. QJ Med 58:69-80, 1986.
161. Lamers KJB, Uitdehaag BMJ, R HO., Doesburg W, Wevers RA, Geel WJA. The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 51:1334-1337, 1988.
162. Warren KG, Catz I, Carroll DJ. Effects of high-to-mega-dose synthetic corticosteroids on multiple sclerosis patients with special reference to cerebrospinal fluid antibodies to myelin basic protein. Clin Neuropharm 10:397-411, 1987.
163. Whitaker JN, Layton BA, Herman PK, Kachelhofer RD, Burgard S, Bartolucci AA. Correlation of myelin basic protein-like material in cerebrospinal fluid of multiple sclerosis patients with their response to glucocorticoid treatment. Ann Neurol 33:10-17, 1993.
164. Whitaker JN. The presence of immunoreactive myelin basic protein peptide in urine of persons with multiple sclerosis. Ann Neurol 22:648-655, 1987.
165. Whitaker JN, Williams PH, Layton BA, McFarland HF, Stone LA, Smith ME, Kachelhofer RD, Bradley EL, Burgard S, Zhao GJ, Paty DW. Correlation of clinical features and findings on cranial magnetic resonance imaging with urinary myelin basic protein-like material in patients with multiple sclerosis. Ann Neurol 35:577-585, 1994.
166. Whitaker JN, Kachelhofer RD, Bradley EL, Burgard S, Layton BA, Reder AT, Morrison W, Zhao GJ, Paty DW. Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol 38:625-632, 1995.
167. Benveniste EN. The role of cytokines in multiple sclerosis/autoimmune encephalitis and other neurological disorders. In: Aggrawal B, Puri R, eds. Human Cytokines: Their Role in Research and Therapy. Boston: Blackwell, 1995, pp 195-216.
168. Merrill JE, Benveniste EN. Cytokines in inflammatory brain lesions: Helpful and harmful. Trends Neurosci 19(8):331-338, 1996.
169. Probert L, Selmaj K. TNF and related molecules: Trends in neuroscience and clinical applications. J Neuroimmunol 72(2):113-117, 1997.
170. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23:339-346, 1988.
171. Robbins DS, Shirazi Y, Drysdale BE, Lieberman A, Shin HS, Shin ML. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J Immunol 139:2593-2597, 1987.
172. Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF. Proliferation of astrocytes in vitro in response to cytokines: A primary role for tumor necrosis factor. J Immunol 144: 129-135, 1990.
173. Lee SJ, Benveniste EN. Adhesion molecule expression and regulation on cells of the central nervous system. J Neuroimmunol 98(2):77-88, 1999.
174. Gallo P, Piccinno MG, Krzalic L, Tavolato B. Tumor necrosis factor alpha (TNFa) and neurological diseases: Failure in detecting TNFa in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumours. J Neuroimmunol 23:41-44, 1989.
175. Merrill JE, Strom SR, Elison GW, Myers LW. In vitro study of mediators of inflammation in multiple sclerosis. J Clin Immunol 9:84-96, 1989.
176. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA. Cytokine accumulations in CSF of multiple sclerosis patients: Frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 40:1735-1739, 1990.
177. Maimone D, Gregory S, Arnason BGW, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 32:67-74, 1991.
178. Franciotta DM, Grimaldi LME, Martino GV, Piccolo G, Bergamaschi R, Citterio A, Melzid’Eril GV. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 26:787-789, 1989.
179. Sharief MK, Hentges R. Association between tumor necrosis factor-a and disease progression in patients with multiple sclerosis. N Engl J Med 325:467-472, 1991.
180. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N, Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 102:230-234, 1991.
181. Sharief MK, Noori MA, Ciardi M, Cirelli A, Thompson EJ. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis: Correlation with TNF-a and blood-brain barrier damage. J Neuroimmunol 43:15-22, 1993.
182. Sharief MK, Thompson EJ. In vivo relationship of tumor necrosis factor-a to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol 38:27-34, 1992.
183. Spuler S, Yousry T, Scheller A, Voltz R, Holler E, Hartmann M, Wick M, Hohlfeld R. Multiple sclerosis: Prospective analysis of TNF-a and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J Neuroimmunol 66(1-2):57-64, 1996.
184. Drulovic J, MostaricaStojkovic M, Levic Z, Stojsavljevic N, Pravica V, Mesaros S. Interleukin-12 and tumor necrosis factor-alpha levels in cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci 147(2):145-150, 1997.
185. Matusevicius D, Navikas V, Soderstrom M, Xiao B-G, Haglund M, Fredrikson S, Link H. Multiple sclerosis: The proinflammatory cytokines lymphotoxin-a and tumour necrosis factor-a are upregulated in cerebrospinal fluid mononuclear cells. J Neuroimmunol 66:115-123, 1996.
186. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53:45-53, 1988.
187. Taga T, Kishimoto T. gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797-819, 1997.
188. Aderka D, Le J, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 143:3517-3523, 1989.
189. Benveniste EN, Tang LP, Law RM. Differential regulation of astrocyte TNF-alpha expression by the cytokines TGF-beta, IL-6 and IL-10. Int J Dev Neurosci 13:341-349, 1995.
190. Shrikant P, Weber E, Jilling T, Benveniste EN. ICAM-1 gene expression by glial cells: Differential mechanisms of inhibition by interleukin-10 and interleukin-6. J Immunol 155:1489-1501, 1995.
191. Oh JW, VanWagoner NJ, RoseJohn S, Benveniste EN. Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression. J Immunol 161(9):4992-4999, 1998.
192. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83:113-118, 1994.
193. Rodriguez M, Pavelko KD, McKinney CW, Leibowitz JL. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol 153(8):3811-3821, 1994.
194. Willenborg DO, Fordham SA, Cowden WB, Ramshaw IA. Cytokines and murine autoimmune encephalomyelitis: inhibition or enhancement of disease with antibodies to select cytokine, or by delivery of exogenous cytokines using a recombinant vaccinia virus system. Scand J Immunol 41:31-41, 1995.
195. Houssiau FA, Bukasa K, Sindic CJM. Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system. Clin Exp Immunol 71:320-323, 1991.
196. Frei K, Fredrikson S, Fontona A, Link H. Interleukin-6 is elevated in plasma in multiple sclerosis. J Neuroimmunol 31:147-153, 1991.
197. Navikas V, Matusevicius D, Soderstrom M, Fredrikson S, Kivisakk P, Ljungdahl A, Hojeberg B, Link H. Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. J Neuroimmunol 64(1):63-69, 1996.
198. Padberg F, Feneberg W, Schmidt S, Schwarz MJ, Korschenhausen D, Greenberg BD, Nolde T, Muller N, Trapmann H, Konig N, Moller HJ, Hampel H. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. J Neuroimmunol 99:218-223, 1999.
199. Tsukada N, Matsuda M, Miyagi K, Yanagisawa N. Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology 43(12):2679-2682, 1993.
200. Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD. A form of circulating ICAM-1 in human serum. J Immunol 147:3788-3793, 1991.
201. Dore-Duffy P, Newman W, Balabanov R, Lisak RP, Mainolfi E, Rothlein R, Peterson M. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: Correlation with clinical activity. Ann Neurol 37:55-62, 1995.
202. Rieckmann P, Martin S, Weichselbraun I, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Luer W, Helwig A, Poser S. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 44(12):2367-2372, 1994.
203. Rieckmann P, Nunke K, Burchhardt M, Albrecht M, Wiltfang J, Ulrich M, Felgenhauer K. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: An indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. J Neuroimmunol 47(2):133-140, 1993.
204. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N. Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. Ann Neurol 33:646-649, 1993.
205. H-P Hartung. Immune-mediated demyelination. Ann Neurol 33(6):563-567, 1993.
206. Droogan AG, Mcmillan SA, Douglas JP, Hawkins SA. Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: Predominant intrathecal release of vascular cell adhesion molecule-1. J Neuroimmunol 64(2):185-191, 1996.
207. Trojano M, Avolio C, Simone LL, Defazio G, Manzari C, De Robertis F, Calo A, Livrea P. Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: Correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings. Neurology 47:1535-1541, 1996.
208. Rieckmann P, Altenhofen B, Riegel A, Baudewig J, Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 41(3):326-333, 1997.
209. Kraus J, Oschmann P, Engelhardt B, Schiel C, Hornig C, Bauer R, Kern A, Traupe H, Dorndorf W. Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis. Acta Neurol Scand 98(2):102-109, 1998.
210. Petersen AA, Sellebjerg F, Frederiksen J, Olesen J, Vejlsgaard GL. Soluble ICAM-1, demyelination, and inflammation in multiple sclerosis and acute optic neuritis. J Neuroimmunol 88(1-2):120-127, 1998.
211. Rieckmann P, Michel U, Albrecht M, Bruck W, Wockel L, Felgenhauer K. Cerebral endothelial cells are a major source for soluble intercellular adhesion molecule-1 in the human central nervous system. Neurosci Lett 186:61-64, 1995.
212. Lyons PD, Benveniste EN. Cleavage of membrane-associated ICAM-1 from astrocytes: Involvement of a metalloprotease. GLIA 22(2):103-112, 1998.
213. Giovannoni G, Lai M, Thorpe J, Kidd D, Chamoun V, Thompson AJ, Miller DH, Feldmann M, Thompson EJ. Longitudinal study of soluble adhesion molecules in multiple sclerosis: Correlation with gadolinium enhanced magnetic resonance imaging. Neurology 48(6):1557-1565, 1997.
214. Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, Frank JA, McFarland HF. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon ß-1b. Ann Neurol 41:669-674, 1997.
215. Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 49(4):1111-1116, 1997.
216. Baumhefner RW, Tourtellote WW, Syndulko K, Ellison G, Myers L, Cohen SN, Shapshak P, Osborne M, Waluch V. Multiple sclerosis (MS): Correlations of quantified magnetic resonance imaged plaque area with clinical disability, instrumented neurologic function measurement (QENF), evoked potentials, and intra-BBB IgG synthesis. Neurology 37(suppl 1):231, 1987.
217. Baumhefner RW, Tourtellote WW, Syndulko K, Ellison G, Myers L, Cohen SN, Shapshak P, Osborne M, Waluch V. Quantitative multiple sclerosis plaque assessment with magnetic resonance imaging: Its correlation with clinical parameters, evoked potentials and intrablood-brain-barrier IgG seynthesis. Arch Neurol 47(8):841-843, 1989.
218. Sand T, Sulg IA. Evoked potentials and CSF-immunoglobulins in MS: Relationship to disease duration, disability, and functional status. Acta Neurol Scand 82:217-221, 1990.
219. Ganes T, Brautaset NJ, Nyberg-Hansen R, Vandvik B. Multimodal evoked responses and cerebrospinal fluid oligoclonal immunoglobulins in patients with multiple sclerosis. Acta Neurol Scand 73:472-476, 1986.
220. Christensen O, Clausen J, Fog T. Relationships between abnormal IgG index, oligoclonal bands, acute phase reactants and some clinical data in multiple sclerosis. J Neurol 218:237-244, 1978.
221. Hutchinson M, Martin EA, Maguire P, Glynn D, Mansfield M, Feighery C. Visual evoked responses and immunoglobulin abnormalities in the diagnosis of multiple sclerosis. Acta Neurol Scand 68:90-95, 1983.
222. Thorpe JW, Kidd D, Moseley IF, Thompson AJ, Macmanus DG, Compston DAS, McDonald WI, Miller DH. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 119(part 3):709-714, 1996.
223. Kidd D, Thorpe JW, Thompson AJ, Kendall BE, Moseley IF, MacManus DG, McDonald WI, Miller DH. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 43:2632-2637, 1993.
224. Durelli L, Cocito D, Riccio A, B C., Bergamasco B, Baggio GF, Perla F, Delsedime M, Gusmaroli G, Bergamini L. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunologic correlations. Neurology 36:238-243, 1986.
225. Tourtellotte WW, Baumhefner RW, Potvin AR, Ma BI, Potvin JH, Mendez M, Syndulko K. Multiple sclerosis de novo CNS IgG synthesis: Effect of ACTH and corticosteroids. Neurology 30:1155-1162, 1980.
226. Baumhefner RW, Tourtellotte WW, Syndulko K, Staugaitis A, Shapshak P. Multiple sclerosis intra-blood-brain-barrier IgG synthesis: Effect of pulse intravenous and intrathecal corticosteroids. Ital J Neurol Sci 10:19-32, 1989.
227. Losy J, Michalowska-Wender G. The effect of large-dose Prednisone therapy on IgG subclasses in multiple sclerosis. Acta Neurol Scand 89:69-71, 1994.
228. Brooks BR, Jubelt B, Cohen S, P O’Donnell, Johnson TR, McKhann GM. Cerebrospinal fluid (CSF) myelin basic protein (MBP) in multiple sclerosis (MS): Effect of prolonged high single-dose alternate-day prednisone therapy. Neurology 29:548, 1979.
229. Olsson JE, Nilsson K. Gammaglobulins of CSF and serum in multiple sclerosis: Isoelectric focusing on polyacrylamide gel and agar gel electrophoresis. Neurology 29:1383-1391, 1979.
230. Hershey LA, Trotter JL. The use and abuse of the cerebrospinal fluid IgG profile in the adult: A practical evaluation. Ann Neurol 8:426-434, 1980.
231. Baumhefner RW, Mendex M, Ma BI, Tourtellotte WW. Modulation of de novo central nervous system (CNS) IgG synthesis with preservation of oligoclonal IgG in multiple sclerosis (MS). Neurology 29:549, 1979.
232. Trotter JL, Garvey WF. Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis. Neurology 30:702-708, 1980.
233. Wajgt A, Gorny MK, Jenek R. The influence of high-dose prednisone medication on autoantibody specific activity and on circulating immune complex level in cerebrospinal fluid of multiple sclerosis patients. Acta Neurol Scand 68:378-385, 1983.
234. Frequin STFM, Lamers KJB, Barkhof F, Borm GF, Hommes OR. Follow-up study of MS patients treated with high-dose intravenous methylprednisolone. Acta Neurol Scand 90:105-110, 1994.
235. Panitch HS, Francis GS, Hooper CJ, Merigan TC, Johnson KP. Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon. Ann Neurol 18:434-438, 1985.
236. Rice GPA, Talbot P, Woelfel EM, et al. Immunological observations in patients with multiple sclerosis treated with human alpha Interferon (abstr). Neurology 34(suppl 1):112, 1984.
237. Confavreux C, Chapuis-Cellier C, Arnaud P, Robert O, Aimard G, Devic M. Oligoclonal '‘fingerprint’’ of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon. J Neurol Neurosurg Psychiatry 49:1308-1312, 1986.
238. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 40:846-852, 1996.
239. Stuve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, Yong VW. Interferon ß-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9. Ann Neurol 40:853-863, 1996.
240. Rosenberg GA, Dencoff JE, Correa N, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury. Neurology 46:1626-1632, 1996.
241. Tourtellotte WW, Murthy K, Brandes D, Sajben N, Ma B, Comiso P, Potvin A, Costanza A, Korelitz J. Schemes to eradicate the multiple sclerosis central nervous system immune reaction (abstr). Neurology 26(6):59-61, 1976.
242. Tourtellotte WW, Potvin AR, Baumhefner RW, Potvin JH, Ma BI, Syndulko K, Petrovich Z. Multiple sclerosis de novo CNS IgG synthesis. Effect of CNS Irradiation. Arch Neurol 37:620-624, 1980.
243. Tourtellotte WW, Potvin AR, Mendez M, Baumhefner RW, Potvin JH, Ma BI, Syndulko K. Failure of intravenous and intrathecal cytarabine to modify central nervous system IgG snythesis in multiple sclerosis. Ann Neurol 8:402-408, 1980.
244. Fazekas F, Deisenhammer F, StrasserFuchs S, Nahler G, Mamoli B. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: Further analyses of the Austrian immunoglobulin in MS study. Mult Scler 3(2):137-141, 1997.
245. Wurster U, Haas J. Passage of intravenous immunoglobulin interaction with the CNS. J Neurol Neurosurg Psychiatry 57:21-25, 1994.